

WP7

Good Practices

The AOK CheckUpPlus for Early Diagnosis in Saxony



Ulrike Rothe

Faculty of Medicine Carl Gustav Carus
Health Sciences/Public Health




Yvonne Lehnert



Why a good practice?

- *A **very innovative screening** and early detection program, resp. **of persons at high risk** for diabetes and following active prevention*
- *AOKplus insured persons (35-65y) **are screened** by the **CheckUpPlus** program in Saxony instead of the statutorily regulated **CheckUp 35***
- *Depending on the **diabetes risk** (according to **FINDRISK**) other additional diagnostics and primary/secondary prevention offerings, resp. are provided*

Flow Chart of Steps of CheckUpPlus



Positive lessons learned

- *Each participant will be individual managed and guided according to his individual risk or an existing condition.*
- *This procedure of the program is unique so far.*

Negative lessons learned

- *The program has not been evaluated yet.*
- *GPs have to use the program better and more.*
- *The transition to prevention offerings must be improved.*
- *Furthermore, GPs recommend often several interventions, but the insured person doesn't use them.*

WP7


Good Practices

The Saxonian Health Care Model (SDMP)



Sächsische Landesärztekammer
Körperschaft des öffentlichen Rechts

Diabetes-Management Program in Saxony between 2000 – 2002 (3. Diabetes Contract)



Why a good practice?

- *The integrated SDMP was **very innovative and implemented everywhere (statewide)** in Saxony with a coverage of nearly **90% of all patients** with diabetes, of **all diabetes specialists** in own practices and of about **80% of all GP's** in Saxony and **was positive evaluated**.*
- *The SDMP could be **a model for implementation** into other European countries, because of the outstanding **cross-sectoral cooperation**, the **good feasibility** with a small documentation and using of secondary data, the **high acceptance rate** and the **significant improvement of the outcome**.*

Reasons for SUCCESS

- *The SDMP was a **bottom-up model** with good adaptations to regional conditions and was **very simple**, especially the valid short documentation, and **without any bureaucracy**.*
- *The **documented data** by physicians for the evaluation as well as for the quarterly feedback reports **were very small**, but covered the **multi-morbidity**.*
- *About more than 50% of all GP's took part in **peer-review-methods**.*
- *Additionally, the pay for performance and especially the already prepared **pay for outcome** contributed to the great success.*


Evaluation Outcome of the SDMP 2000-2002

Saxon Diabetes Management – based on integrated care structures and cross-sectoral practice guidelines – resulted in:

- I) an early referral of the patients from GP into specialized care, followed by better HbA1c and blood pressure values**
- II) a substantial improvement of diabetes care**
- III) an equalization of regional differences of quality of diabetes care under the influence of homogeneously promoted therapeutic strategies by the guidelines**


I) HbA1c values of patients with first transfer from GP to diabetes specialized practices

Before implementation of guideline
observation phase 07/1996 – 12/1996




Mean = 8.8 %
SD = 2.28
Median = 8.5 %
n = 682

After implementation of guideline
observation phase 07/2002 – 10/2002





Mean = 7.8 %
SD = 1.77
Median = 7.5 %
n = 279

II) Mean HbA1c value in Saxony




$7,1 \pm 1,3\% \Rightarrow 6,8 \pm 1,2\%$



WWW.CHRODIS.EU

Improvement of metabolic control (HbA1c)



mittlere initiale
HbA1c-Werte

> 7,5%	8,8% (N=32.314)	8,3% (N=29.044)	8,1% (N=28.939)	8,0% (N=29.818)	8,0% (N=29.053)	8,0% (N=29.771)	7,7% (N=29.671)	7,7% (N=29.929)	7,8% (N=30.059)	7,7% (N=30.156)	7,6% (N=29.939)	7,5% (N=32.314)
6,2 - 7,5%	6,8% (N=46.781)	6,8% (N=67.526)	6,9% (N=67.526)	6,9% (N=67.526)	6,9% (N=67.526)	6,9% (N=67.526)	6,8% (N=67.526)	6,8% (N=67.526)	6,9% (N=67.526)	6,9% (N=67.526)	6,9% (N=67.526)	6,8% (N=67.526)
≤ 6,1%	5,7% (N=26.109)	6,0% (N=54.506)	6,0% (N=54.506)	6,1% (N=54.506)	6,1% (N=54.506)	6,2% (N=54.506)	6,1% (N=54.506)	6,1% (N=54.506)	6,2% (N=54.506)	6,2% (N=54.506)	6,2% (N=54.506)	6,2% (N=54.506)
missings	(N=0)	(N=12.150)	(N=12.391)	(N=9.226)	(N=10.882)	(N=9.346)	(N=9.904)	(N=8.662)	(N=8.426)	(N=7.963)	(N=8.697)	(N=0)

Medizinische Fakultät Carl Gustav Carus der TU-Dresden
Stand August 2007

Risk distribution according to vascular complications based on both: HbA1c + Blood Pressure

Observation time I / 2000 (n = 105.204)

HbA1c \ BP	low	moderate	high
low	3,3%	10,3%	11,2%
moderate	4,9%	18,0%	21,5%
high	3,1%	11,3%	16,3%

Risk level

HbA1c

- ≤ 6,5 %
- 6,6 - 7,5 %
- > 7,5 %

Blood pressure

- ≤ 130/80 mmHg
- 131/81 - 140/90
- > 140/90 mmHg

Observation time IV / 2002 (n = 105.204)

HbA1c \ BP	low	moderate	high
low	4,8%	12,8%	9,3%
moderate	7,4%	24,1%	19,6%
high	2,8%	9,4%	9,8%

DMAA

Disease Management Association of America

2005 DMLF

BRONZE AWARD

GENERAL POSTER PROGRAM

WWW.CHRODIS.EU

 **CHRODIS**
ADDRESSING CHRONIC DISEASES & HEALTHY AGEING ACROSS THE LIFE CYCLE

Evaluation of a Diabetes Management System Based on Practice Guidelines, Integrated Care, and Continuous Quality Management in a Federal State of Germany

A population-based approach to health care research

ULRIKE ROTHE, MD¹
GABRIELE MÜLLER, MPH¹
PETER E.H. SCHWARZ, MD²
MARTIN SEIFERT, MSC¹
HILDEBRAND KUNATH, PHD, MD¹
RAINER KOCH, PHD¹

SYBILLE BERGMANN, PHD³
ULRICH JULIUS, PHD, MD²
STEFAN R. BORNSTEIN, PHD, MD²
MARKOLF HANEFELD, PHD, MD⁴
JAN SCHULZE, PHD, MD^{2,5}

The growing interest in evidence-based medicine and outcome and a commitment to integrated care across primary and secondary care sectors all contribute to making disease management an attractive idea (1). The disease

OBJECTIVE — The aim of this study was to evaluate a diabetes management system (SDMP), which is based on integrated care and continuous quality management. The SDMP was implemented into diabetes contracts between health insurance providers, general practitioners (GPs), and diabetes specialized practitioners (DSPs) unified in the Saxon association of Statutory Health Insurance Physicians.

RESEARCH DESIGN AND METHODS — The evaluation of the SDMP in Germany represents a real-world study by using clinical data collected from participating physicians.

Diabetes Care 31:863–868, 2008

largely untested, making evaluation essential.

There is evidence of regional variations in diabetes management in different primary care settings within the same

Cross-Sectoral Practice-Guidelines

www.ag-sachsen.de

DIABETES mellitus Typ 1

Fachkommission Diabetes Sachsen
In Zusammenarbeit mit dem Sächsischen Berufsverband der Fachärzte für Allgemeinmedizin und der Sächsischen Gesellschaft für Stoffwechsellkrankheiten und Endokrinopathien
Unterstützt durch die Kassenzärztliche Vereinigung Sachsen, Thüringen, Sachsen-Anhalt, Mecklenburg-Vorpommern und Brandenburg
Gefördert durch das Bundesministerium für Gesundheit

Kinder und Jugendliche mit DIABETES mellitus Typ 1

Fachkommission Diabetes Sachsen
In Zusammenarbeit mit dem Berufsverband der Ärzte für Kinderheilkunde und Jugendmedizin, Landesverband Sachsen
Der Sächsisch-Thüringischen Gesellschaft für Kinder- und Jugendmedizin und

DIABETES und Schwangerschaft

Fachkommission Diabetes Sachsen
In Zusammenarbeit mit dem Sächsischen Berufsverband der Frauenärzte
Der Sächsischen Gesellschaft für Frauenheilkunde und Geburtshilfe und
Der Sächsischen Gesellschaft für Stoffwechsellkrankheiten und Endokrinopathien
Unterstützt durch die Kassenz

DIABETISCHE KOMPLIKATIONEN Augen-

Sächsische Landesärztekammer
Landesärztekammer und KV Thüringen
Ärztekammer Sachsen-Anhalt
Landesärztekammer Brandenburg
Ärztekammer Mecklenburg-Vorpommern

DIABETES mellitus Typ 2

Fachkommission Diabetes Sachsen
In Zusammenarbeit mit dem Sächsischen Berufsverband der Fachärzte für Allgemeinmedizin und der Sächsischen Gesellschaft für Stoffwechsellkrankheiten und Endokrinopathien
Unterstützt durch die Kassenzärztliche Vereinigung Sachsen, Thüringen, Sachsen-Anhalt, Mecklenburg-Vorpommern und Brandenburg
Gefördert durch das Bundesministerium für Gesundheit

Praxis-Leitlinie zur DIAGNOSTIK THERAPIE von FETTSTOFFWECHSELSTÖRUNGEN

Volume 7 2016

Fachkommission Diabetes Sachsen
In Zusammenarbeit mit einem unabhängigen wissenschaftlichen Beirat von Experten verschiedener Fachdisziplinen
Gefördert durch das MEDDRIVE-Projekt der TU Dresden

Praxis-Leitlinie METABOLISCH-VASKULÄRES SYNDROM (MVS)

Volume 3 2016

Fachkommission Diabetes Sachsen
In Zusammenarbeit mit einem unabhängigen wissenschaftlichen Beirat von Experten verschiedener Fachdisziplinen

GLOSSAR

DIABETISCHE KOMPLIKATIONEN Nephropathie

Sächsische Landesärztekammer
Landesärztekammer und KV Thüringen
Ärztekammer Sachsen-Anhalt
Landesärztekammer Brandenburg
Ärztekammer Mecklenburg-Vorpommern

DIABETISCHE KOMPLIKATIONEN Fuß-Syndrom

Sächsische Landesärztekammer
Landesärztekammer und KV Thüringen
Ärztekammer Sachsen-Anhalt
Landesärztekammer Brandenburg
Ärztekammer Mecklenburg-Vorpommern

Volume 11 2010

2017

Integrative Guideline

MVS

Guideline
Diabetes

Guideline
Hypertension

Guideline
Lipid disorders

Chronic Care
Model
(Multimorbidity!)

Interdisciplinary
Practice teams

Patient
Empowerment

Cooperative
Decision making

Longitudinal
Monitoring

The Joint Action on Chronic Diseases and promoting healthy ageing across the life cycle (JA-CHRODIS)*

*** THIS PRESENTATION ARISES FROM THE JOINT ACTION ON CHRONIC DISEASES AND PROMOTING HEALTHY AGEING ACROSS THE LIFE CYCLE (JA-CHRODIS) WHICH HAS RECEIVED FUNDING FROM THE EUROPEAN UNION, IN THE FRAMEWORK OF THE HEALTH PROGRAMME (2008-2013)**

